{
    "clinical_study": {
        "@rank": "14934", 
        "arm_group": {
            "arm_group_label": "HAVG graft", 
            "arm_group_type": "Experimental", 
            "description": "HAVG graft implantation to study participants."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety and efficacy of a novel, tissue-engineered\n      vascular prosthesis, the Human Acellular Vascular Graft, HAVG.\n\n      The HAVG is intended as an alternative to synthetic materials and to autologous grafts in\n      the creation of an above-knee femoro-popliteal bypass graft in patients with peripheral\n      arterial disease."
        }, 
        "brief_title": "Evaluation of the Safety and Efficacy of a Vascular Prosthesis as an Above-Knee Bypass Graft in Patients With Peripheral Arterial Disease", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Peripheral Arterial Disease", 
            "Peripheral Vascular Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Vascular Diseases", 
                "Peripheral Vascular Diseases", 
                "Peripheral Arterial Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "The HAVG is a sterile, non-pyrogenic, acellular tubular graft composed of human collagens\n      and other natural extra-cellular matrix proteins. Upon implantation, it is anticipated\n      (based on pre-clinical studies) that the collagen-based matrix comprising the graft will be\n      infiltrated with host cells and re-modeled by the host. This will result in a vascular\n      structure more similar to the histological composition of the native vascular tissue that\n      may improve graft longevity and be less likely to become infected."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with symptomatic peripheral arterial disease who require above knee\n             femoro-popliteal bypass surgery\n\n          -  Claudication distance of 200 m or less or rest pain or critical limb ischemia\n\n          -  Preoperative angiography or angio-CT shows superficial femoral artery occlusion of\n             >10 cm AND graft length required \u2264 30 cm. This imaging may have been conducted up to\n             3 months prior to study entry provided that the patient's symptoms have remained\n             stable since that time\n\n          -  Preoperative imaging shows at least two below knee vessels patent to the ankle with\n             good runoff\n\n          -  Femoral artery occlusion is not considered suitable for endovascular treatment\n\n          -  Autologous vein grafts are not suitable or feasible e.g. because of severe venous\n             disease or prior use of leg veins for other bypass surgery or there is a clinical\n             need to preserve those veins for future bypass surgery in the coronary or peripheral\n             circulation\n\n          -  Aged 18 to 80 years old, inclusive\n\n          -  Hemoglobin \u2265 10 g/dL and platelet count \u2265 100,000/mm3 prior to Day 1\n\n          -  Other hematological and biochemical parameters within a range considered acceptable\n             for the administration of general anesthesia prior to Day 1\n\n          -  Adequate liver function, defined as serum bilirubin \u2264 1.5 mg/dL; GGT, AST, ALT, and\n             alkaline phosphatase \u2264 2x upper limit of normal or INR \u2264 1.5 prior to Day 1.\n\n          -  Able to communicate meaningfully with investigative staff, competent to give written\n             informed consent, and able to comply with entire study procedures\n\n          -  Able and willing to give informed consent\n\n          -  Life expectancy of at least 2 years\n\n        Exclusion Criteria:\n\n          -  History or evidence of severe cardiac disease (NYHA Functional Class III or IV),\n             myocardial infarction within six months prior to study entry (Day 1), ventricular\n             tachyarrhythmias requiring continuing treatment, or unstable angina\n\n          -  Acute injury or active infection (including positive cultures of pathogenic bacteria)\n             in the limb receiving the graft\n\n          -  Stroke within six (6) months prior to study entry (Day 1)\n\n          -  Treatment with any investigational drug or device within 60 days prior to study entry\n             (Day 1)\n\n          -  Women of child bearing potential\n\n          -  Active diagnosis of cancer within the previous year\n\n          -  Immunodeficiency including AIDS / HIV\n\n          -  Documented hypercoagulable state or history of 2 or more DVTs or other spontaneous\n             intravascular thrombotic events\n\n          -  Bleeding diathesis\n\n          -  Ongoing treatment with vitamin K antagonists or direct thrombin inhibitors or factor\n             Xa inhibitors (e.g. dabigatran, apixaban or rivaroxaban)\n\n          -  Previous arterial bypass surgery (autologous vein or synthetic graft) in the\n             operative limb\n\n          -  Previous angioplasty with stenting in the operative limb unless the graft anastomoses\n             can be made at least 1cm distant from the site of the stent\n\n          -  Stenosis of >50% of the external iliac artery unless it is planned to treat this\n             stenosis with angioplasty with or without stenting prior to, or at the time of, graft\n             implantation\n\n          -  Distal graft anastomosis likely to be below the knee\n\n          -  Active autoimmune disease - symptomatic or requiring ongoing drug therapy\n\n          -  Active local or systemic infection (WBC > 15,000/mm3)\n\n          -  Known serious allergy to aspirin or penicillin\n\n          -  Any other condition which in the judgment of the investigator would preclude adequate\n             evaluation of the safety and efficacy of the HAVG\n\n          -  Previous enrollment in this study\n\n          -  Employees of the sponsor or patients who are employees or relatives of the\n             investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01872208", 
            "org_study_id": "CLN-PRO-V002"
        }, 
        "intervention": {
            "arm_group_label": "HAVG graft", 
            "description": "Patients will be implanted with a Human Acellular Vascular Graft (HAVG) as an above-knee femoro-popliteal bypass graft using standard vascular surgical techniques. The graft will be placed in a straight or curved configuration.", 
            "intervention_name": "HAVG graft implantation", 
            "intervention_type": "Device", 
            "other_name": "Human Acellular Vascular Graft"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "PAD", 
            "Atherosclerosis", 
            "Peripheral circulation", 
            "Blood Vessel Prosthesis", 
            "Tissue-Engineered Vascular Graft", 
            "Vascular Prosthesis Implantation", 
            "Femoro-Popliteal Bypass"
        ], 
        "lastchanged_date": "January 13, 2014", 
        "location": [
            {
                "contact": {
                    "email": "tomzubil@poczta.onet.pl", 
                    "last_name": "Tomasz Zubilewicz, Prof.Dr.Med.", 
                    "phone": "+48 81 5325 707"
                }, 
                "facility": {
                    "address": {
                        "city": "Lublin", 
                        "country": "Poland", 
                        "zip": "20-081"
                    }, 
                    "name": "Clinic of Vascular Surgery and Angiology; Medical University in Lublin"
                }, 
                "investigator": {
                    "last_name": "Tomasz Zubilewicz, Prof.Dr.Med.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Piotr_gutowski@poczta.onet.pl", 
                    "last_name": "Piotr Gutowski, Prof.Dr.Med.", 
                    "phone": "+48 91 466 1156"
                }, 
                "facility": {
                    "address": {
                        "city": "Szczecin", 
                        "country": "Poland", 
                        "zip": "70-111"
                    }, 
                    "name": "Pomeranian University in Szczecin; Clinic of General, Vascular Surgery and Angiology"
                }, 
                "investigator": {
                    "last_name": "Piotr Gutowski, Prof.Dr.Med.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "witkiewicz@wssk.wroc.pl", 
                    "last_name": "Wojciech Witkiewicz, Prof.dr.med.", 
                    "phone": "+48 71 32 70 336"
                }, 
                "facility": {
                    "address": {
                        "city": "Wroc\u0142aw", 
                        "country": "Poland", 
                        "zip": "51-124"
                    }, 
                    "name": "Regional Specialist Hospital in Wroclaw; Clinic of Vascular Surgery"
                }, 
                "investigator": {
                    "last_name": "Wojciech Witkiewicz, Prof.Dr.med.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Poland"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Study for Evaluation of the Safety and Efficacy of Humacyte's Human Acellular Vascular Graft as an Above-Knee Femoro-Popliteal Bypass Graft in Patients With Peripheral Arterial Disease", 
        "overall_contact": {
            "email": "pilgrim@humacyte.com", 
            "last_name": "Alison J Pilgrim, BM BCh Phil", 
            "phone": "+1 919 313 9633"
        }, 
        "overall_official": {
            "affiliation": "Humacyte, Inc.", 
            "last_name": "Alison J Pilgrim, BM MCh Phil", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Poland: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The incidence of aneurysm formation, anastomotic bleeding or rupture, graft infection and irritation/inflammation/infection at the implantation site will be assessed by Doppler ultrasound and tabulated.", 
                "measure": "Change in HAVG graft characteristics", 
                "safety_issue": "Yes", 
                "time_frame": "From day 5 to month 24 after HAVG implantation."
            }, 
            {
                "description": "Determine the patency (primary, primary assisted and secondary) rate of the Humacyte HAVG by Doppler ultrasound.", 
                "measure": "Change in HAVG patency rate", 
                "safety_issue": "No", 
                "time_frame": "From day 5 to month 24 after HAVG implantation."
            }, 
            {
                "description": "Frequency and severity of AEs of each patient will be documented.", 
                "measure": "Change in frequency and severity of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "From day 1 to month 24 after HAVG implantation."
            }, 
            {
                "description": "Change from baseline in hematology, coagulation and clinical chemistry parameters.", 
                "measure": "Change in hematology, coagulation and clinical chemistry parameters", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline to week 26 after HAVG implantation."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01872208"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Assess changes in the Panel Reactive Antibody response over 6 months after graft implantation.", 
                "measure": "Change from baseline in Panel Reactive Antibody (PRA)", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline to week 26 after HAVG implantation."
            }, 
            {
                "description": "Determine whether IgG antibodies to the extracellular matrix material are formed in response to implantation of the HAVG over the 6 months after implantation.", 
                "measure": "Development of IgG antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline to week 26 after HAVG implantation."
            }, 
            {
                "description": "To determine the patency rates of the graft (primary, primary assisted and secondary).", 
                "measure": "HAVG patency rates", 
                "safety_issue": "No", 
                "time_frame": "At months 6, 12, 18 after HAVG implantation."
            }, 
            {
                "description": "Determine the rates of interventions needed to maintain / restore patency in the graft.", 
                "measure": "Graft interventions", 
                "safety_issue": "No", 
                "time_frame": "At days 5, 15, weeks 6, 12, 16, months 12, 18, 24 after HAVG implantation."
            }, 
            {
                "description": "Assessment of any effect of graft implantation on claudication, rest pain and ischemic ulcers.", 
                "measure": "Effect of graft implantation on PAD symptoms", 
                "safety_issue": "No", 
                "time_frame": "From baseline to weeks 6, 12, 26, months 12, 18, 24 after HAVG implantation."
            }, 
            {
                "description": "Assessment of any effect of the graft on ankle-brachial index (ABI).", 
                "measure": "Effect of graft on ankle-brachial index (ABI)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to weeks 6, 12, 26, months 12, 18, 24 afer HAVG implantation."
            }
        ], 
        "source": "Humacyte, Inc.", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "FGK Clinical Research Sp. zo.o.", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "FGK Clinical Research GmbH", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Humacyte, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}